knowledge -WSS

knowledge

author：knowledge 2025-10-02 22:40:26 - browse：579

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

knowledge

WSS

Gene therapy denied for Afghan refugee whose father aided U.S.

Surprise medical billing ban raises prices elsewhere

Opioid cravings were reduced by anti

As AI regulations shape up, health tech startups beg for clarity

Hospitals are piloting generative AI tools as regulators play catch

Study suggests new cause of Down syndrome: cells linked to aging

leisure time

knowledge

explore

Anesthesiologist group: stop taking Ozempic before surgery

At JPM 2024, hospital systems pitch financial strength to investors

Walensky prepares to leave CDC — and Congress — behind

Medicare Advantage coverage denials need scrutiny, senators say

Virginia high school admissions case could be legal follow

Life science postdocs should get big pay hike, NIH panel says

Virginia high school admissions case could be legal follow

Measles policy set amid Florida outbreak alarms vaccine proponents

Continuity nursing helped my family in our darkest PICU moments

Ascension's ugly legal battle over care for poor patients in Texas

focus

Researchers tackle phage therapy hurdles for wider adoption

Profiling embryos to choose those with higher IQs is almost a reality

Elevance, SCAN deals highlight health insurer acquisition scrutiny

MD Anderson's Padmanee Sharma responds to research credit suit

Weight loss drugs aren’t covered by Obamacare. That may change

New CMS data security rules will hurt Medicare, Medicaid research

knowledge

knowledge

explore

leisure time